John C Morris

List of Publications by Citations

430 papers	76,732 citations	118 h-index	275 g-index
451 ext. papers	91,169 ext. citations	8.8 avg, IF	7.72 L-index

#	Paper	IF	Citations
430	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's and Dementia*, **2011**, 7, 263-9	1.2	8211
429	The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*, **1993**, 43, 2412-4	6.5	6096
428	Current concepts in mild cognitive impairment. *Archives of Neurology*, **2001**, 58, 1985-92		3473
427	Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature*, **1998**, 393, 702-5	50.4	2903
426	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *New England Journal of Medicine*, **2012**, 367, 795-804	59.2	2272
425	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature Genetics*, **2009**, 41, 1088-93	36.3	2018
424	Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *Journal of Neuroscience*, **2005**, 25, 7709-17	6.6	1550
423	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature Genetics*, **2011**, 43, 429-35	36.3	1421
422	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nature Genetics*, **2011**, 43, 436-41	36.3	1367
421	Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Annals of Neurology*, **1999**, 45, 358-68	9.4	1360
420	Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *Journal of Neuroscience*, **1996**, 16, 4491-500	6.6	1359
419	Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science*, **2010**, 330, 1774	33.3	1349
418	Mild cognitive impairment represents early-stage Alzheimer disease. *Archives of Neurology*, **2001**, 58, 397-405		1179
417	Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *Journal of Neuropathology and Experimental Neurology*, **2012**, 71, 362-81	3.1	1145
416	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Annals of Neurology*, **2006**, 59, 512-9	9.4	1009
415	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A□ tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
414	A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. *NeuroImage*, **2004**, 23, 724-38	7.9	905

413	Alzheimer's disease: the challenge of the second century. *Science Translational Medicine*, **2011**, 3, 77sr1	17.5	893
412	Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *International Psychogeriatrics*, **1997**, 9 Suppl 1, 173-6; discussion 177-8	3.4	888
411	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1924-38	27.4	842
410	Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. *Archives of Neurology*, **2007**, 64, 343-9		727
409	Human apoE isoforms differentially regulate brain amyloid-peptide clearance. *Science Translational Medicine*, **2011**, 3, 89ra57	17.5	721
408	The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. *Cerebral Cortex*, **2009**, 19, 497-510	5.1	669
407	APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Annals of Neurology*, **2010**, 67, 122-31	9.4	618
406	Functional deactivations: change with age and dementia of the Alzheimer type. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 14504-9	11.5	602
405	Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. *Archives of Neurology*, **1998**, 55, 326-35		579
404	Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. *Nature Medicine*, **2019**, 25, 270-276	50.5	577
403	The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. *Alzheimer Disease and Associated Disorders*, **2006**, 20, 210-6	2.5	568
402	A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. *New England Journal of Medicine*, **1992**, 327, 1253-9	59.2	546
401	The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. *Alzheimer Disease and Associated Disorders*, **2009**, 23, 91-101	2.5	525
400	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*, **2017**, 549, 523-527	50.4	520
399	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
398	Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. *Neurobiology of Aging*, **2009**, 30, 1026-36	5.6	485
397	Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. *Archives of Neurology*, **2001**, 58, 1395-402		433
396	Tau and A imaging, CSF measures, and cognition in Alzheimer's disease. *Science Translational Medicine*, **2016**, 8, 338ra66	17.5	418

395	Sleep quality and preclinical Alzheimer disease. *JAMA Neurology*, **2013**, 70, 587-93	17.2	414
394	Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4441-6	11.5	407
393	The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. *Alzheimer Disease and Associated Disorders*, **2007**, 21, 249-58	2.5	397
392	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. *Lancet Neurology, The*, **2013**, 12, 957-65	24.1	389
391	Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. *Journal of Neuroscience*, **2012**, 32, 8890-9	6.6	385
390	TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. *American Journal of Pathology*, **2007**, 171, 227-40	5.8	376
389	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. *Nature Medicine*, **2019**, 25, 277-283	50.5	375
388	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. *Alzheimer's and Dementia*, **2012**, 8, S1-68	1.2	368
387	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nature Genetics*, **2010**, 42, 234-9	36.3	361
386	Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. *Journal of Molecular Neuroscience*, **2001**, 17, 101-18	3.3	359
385	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. *Nature*, **2020**, 581, 71-76	50.4	356
384	Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. *Archives of Neurology*, **2009**, 66, 1469-75		350
383	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature*, **2014** , 505, 550-554	50.4	345
382	Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. *Archives of Neurology*, **2010**, 67, 1473-84		330
381	Validation of clinical diagnostic criteria for Alzheimer's disease. *Annals of Neurology*, **1988**, 24, 17-22	9.4	327
380	Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. *Alzheimer's and Dementia*, **2010**, 6, 239-46	1.2	308
379	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. *Biological Psychiatry*, **2010**, 68, 903-12	7.9	298
378	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. *Alzheimer's and Dementia*, **2013**, 9, e111-94	1.2	296

377	Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. *EMBO Molecular Medicine*, **2009**, 1, 371-80	12	278
376	Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 17763-7	11.5	275
375	Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. *Annals of Neurology*, **2009**, 65, 176-83	9.4	272
374	Validity and reliability of the AD8 informant interview in dementia. *Neurology*, **2006**, 67, 1942-8	6.5	272
373	At the interface of sensory and motor dysfunctions and Alzheimer's disease. *Alzheimer's and Dementia*, **2015**, 11, 70-98	1.2	271
372	Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. *Neurology*, **2014**, 83, 253-60	6.5	266
371	Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimer's and Dementia*, **2017**, 13, 841-849	1.2	266
370	GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. *Neuron*, **2013**, 78, 256-68	13.9	255
369	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4502-9	11.5	253
368	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. *Annals of Neurology*, **2016**, 79, 929-39	9.4	247
367	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. *Archives of Neurology*, **2009**, 66, 1476-81		247
366	High-precision plasma β amyloid 42/40 predicts current and future brain amyloidosis. *Neurology*, **2019**, 93, e1647-e1659	6.5	245
365	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Science Translational Medicine*, **2014**, 6, 226ra30	17.5	244
364	Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. *Neurology*, **2006**, 67, 467-73	6.5	231
363	Functional connectivity and graph theory in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 757-68	5.6	230
362	Accelerated weight loss may precede diagnosis in Alzheimer disease. *Archives of Neurology*, **2006**, 63, 1312-7		230
361	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurology, The*, **2018**, 17, 241-250	24.1	224
360	Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 14968-73	11.5	218

359	The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. *Neurology*, **2009**, 72, 1048-55	6.5	213
358	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. *Alzheimer's and Dementia*, **2015**, 11, e1-120	1.2	206
357	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. *Annals of Neurology* , **2010**, 68, 311-8	9.4	205
356	Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. *Neurobiology of Aging*, **2009**, 30, 432-40	5.6	203
355	Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. *Neurology*, **2007**, 68, 666-9	6.5	201
354	On the path to 2025: understanding the Alzheimer's disease continuum. *Alzheimer's Research and Therapy*, **2017**, 9, 60	9	197
353	Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. *Archives of Neurology*, **2012**, 69, 636-43		196
352	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. *JAMA Neurology*, **2015**, 72, 1029-42	17.2	190
351	Effects of age and amyloid deposition on A□dynamics in the human central nervous system. *Archives of Neurology*, **2012**, 69, 51-8		185
350	Longitudinal driving performance in early-stage dementia of the Alzheimer type. *Journal of the American Geriatrics Society*, **2003**, 51, 1342-7	5.6	185
349	Rates of progression in mild cognitive impairment and early Alzheimer's disease. *Neurology*, **2002**, 59, 1034-41	6.5	182
348	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between □Amyloid and Tauopathy. *JAMA Neurology*, **2016**, 73, 1070-7	17.2	179
347	A novel Alzheimer disease locus located near the gene encoding tau protein. *Molecular Psychiatry*, **2016**, 21, 108-17	15.1	175
346	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology*, **2012**, 79, 897-905	6.5	175
345	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. *Neurology*, **2013**, 80, 1784-91	6.5	175
344	Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). *Alzheimer Disease and Associated Disorders*, **2018**, 32, 10-17	2.5	174
343	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. *JAMA Neurology*, **2018**, 75, 582-590	17.2	166
342	Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. *Archives of Neurology*, **2009**, 66, 1557-62		165

341	Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. *Archives of Neurology*, **2008**, 65, 1467-71		163
340	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*, **2020**, 26, 398-407	50.5	160
339	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. *Alzheimer's and Dementia*, **2017**, 13, e1-e85	1.2	157
338	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. *Science Translational Medicine*, **2016**, 8, 369ra178	17.5	155
337	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's and Dementia*, **2019**, 15, 106-152	1.2	153
336	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. *JAMA Neurology*, **2015**, 72, 1275-80	17.2	152
335	Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. *Annals of Neurology*, **1988**, 23, 477-84	9.4	151
334	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. *Human Molecular Genetics*, **2012**, 21, 4558-71	5.6	150
333	Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. *Archives of Neurology*, **2009**, 66, 638-45		148
332	Effect of sleep on overnight cerebrospinal fluid amyloid kinetics. *Annals of Neurology*, **2018**, 83, 197-204	9.4	147
331	Increased in vivo amyloid-42 production, exchange, and loss in presenilin mutation carriers. *Science Translational Medicine*, **2013**, 5, 189ra77	17.5	144
330	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. *Clinical Investigation*, **2012**, 2, 975-984		144
329	The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. *NeuroImage*, **2013**, 76, 332-44	7.9	140
328	Partial volume correction in quantitative amyloid imaging. *NeuroImage*, **2015**, 107, 55-64	7.9	138
327	Comparison of analytical platforms for cerebrospinal fluid measures of amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. *Archives of Neurology*, **2011**, 68, 1137-44		138
326	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. *Alzheimer's and Dementia*, **2017**, 13, 561-571	1.2	137
325	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. *Alzheimer's and Dementia*, **2015**, 11, 865-84	1.2	132
324	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. *Neurology*, **2018**, 91, e1295-e1306	6.5	129

323	Quantitative analysis of PiB-PET with FreeSurfer ROIs. *PLoS ONE*, **2013**, 8, e73377	3.7	126
322	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. *Brain*, **2016**, 139, 2249-60	11.2	125
321	Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. *Science Translational Medicine*, **2019**, 11,	17.5	123
320	Loss of Brain Aerobic Glycolysis in Normal Human Aging. *Cell Metabolism*, **2017**, 26, 353-360.e3	24.6	121
319	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 64-74	24.1	121
318	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. *Alzheimer's and Dementia*, **2018**, 14, 1460-1469	1.2	120
317	Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. *Archives of Neurology*, **2007**, 64, 725-30		120
316	Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 55, 813-822	4.3	120
315	Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. *Archives of Neurology*, **2011**, 68, 581-6		119
314	Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiology of Aging*, **2016**, 41, 200.e13-200.e20	5.6	119
313	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nature Communications*, **2020**, 11, 2612	17.4	118
312	Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. *JAMA Neurology*, **2016**, 73, 561-71	17.2	118
311	Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. *Annals of Neurology*, **2011**, 70, 857-61	9.4	118
310	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. *Nature Neuroscience*, **2019**, 22, 1903-1912	25.5	118
309	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. *JAMA Neurology*, **2019**, 76, 264-273	17.2	117
308	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*, **2018**, 91, e859-e866	6.5	116
307	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. *Neurology*, **2013**, 81, 736-44	6.5	115
306	Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. *Annals of Neurology*, **2011**, 70, 274-85	9.4	113

305	An antidepressant decreases CSF A production in healthy individuals and in transgenic AD mice. *Science Translational Medicine*, **2014**, 6, 236re4	17.5	111
304	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. *Acta Neuropathologica Communications*, **2013**, 1, 65	7.3	110
303	Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. *Archives of Neurology*, **2012**, 69, 700-8		110
302	Differences in the A40/A42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. *Annals of Neurology*, **2000**, 48, 201-210	9.4	110
301	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. *Acta Neuropathologica*, **2017**, 133, 839-856	14.3	107
300	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. *Alzheimer Disease and Associated Disorders*, **2018**, 32, 351-358	2.5	107
299	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. *Alzheimer's and Dementia*, **2017**, 13, 727-738	1.2	106
298	PET amyloid-beta imaging in preclinical Alzheimer's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 370-9	6.9	102
297	Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. *Archives of Neurology*, **2005**, 62, 1821-30		102
296	"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis. *Neurology*, **2015**, 84, 617-22	8.5	101
295	Spatial Navigation in Preclinical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 52, 77-90	4.3	101
294	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. *Alzheimer's Research and Therapy*, **2013**, 5, 48	9	100
293	Age and amyloid effects on human central nervous system amyloid-beta kinetics. *Annals of Neurology*, **2015**, 78, 439-53	9.4	98
292	Association of Cerebral Amyloid- Aggregation With Cognitive Functioning in Persons Without Dementia. *JAMA Psychiatry*, **2018**, 75, 84-95	14.5	94
291	SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. *PLoS Genetics*, **2010**, 6, e1001101	6	90
290	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurology, The*, **2020**, 19, 145-156	24.1	90
289	Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. *Archives of Neurology*, **2011**, 68, 1013-9		87
288	Missense variant in TREML2 protects against Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 1510.e19-26	5.6	84

287	Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. *PLoS Genetics*, **2014**, 10, e1004758	6	84
286	OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease		81
285	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. *Alzheimer's Research and Therapy*, **2015**, 7, 59	9	80
284	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. *Brain*, **2010**, 133, 3290-300	11.2	77
283	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. *NeuroImage*, **2017**, 161, 171-178	7.9	76
282	Absence of practice effects in preclinical Alzheimer's disease. *Neuropsychology*, **2015**, 29, 940-8	3.8	73
281	Persistent metabolic youth in the aging female brain. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 3251-3255	11.5	72
280	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. *Brain*, **2018**, 141, 3065-3080	11.2	72
279	Measuring and estimating diagnostic accuracy when there are three ordinal diagnostic groups. *Statistics in Medicine*, **2006**, 25, 1251-73	2.3	71
278	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. *Brain*, **2019**, 142, 1063-1076	11.2	71
277	Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. *Alzheimer's and Dementia*, **2018**, 14, 205-214	1.2	70
276	Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. *Journal of the American Geriatrics Society*, **1990**, 38, 129-35	5.6	69
275	Functional connectivity in autosomal dominant and late-onset Alzheimer disease. *JAMA Neurology*, **2014**, 71, 1111-22	17.2	68
274	Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. *JAMA Neurology*, **2013**, 70, 1242-8	17.2	68
273	Comparison of a single-channel EEG sleep study to polysomnography. *Journal of Sleep Research*, **2016**, 25, 625-635	5.8	68
272	Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. *Alzheimer's and Dementia*, **2013**, 9, S39-44	1.2	67
271	Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. *Annals of Neurology*, **2007**, 61, 446-53	9.4	67
270	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. *JAMA Neurology*, **2015**, 72, 656-65	17.2	66

269	Data-driven models of dominantly-inherited Alzheimer's disease progression. *Brain*, **2018**, 141, 1529-1544	11.2	66
268	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. *Alzheimer's Research and Therapy*, **2019**, 11, 71	9	66
267	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. *Annals of Neurology*, **2016**, 80, 379-87	9.4	65
266	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. *Neurobiology of Aging*, **2016**, 44, 1-8	5.6	65
265	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). *Lancet Neurology, The*, **2016**, 15, 1317-1325	24.1	64
264	Longitudinal □Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. *JAMA Neurology*, **2016**, 73, 1192-1200	17.2	63
263	Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. *Journal of the American Geriatrics Society*, **2003**, 51, 819-23	5.6	63
262	Driving and dementia of the Alzheimer type: beliefs and cessation strategies among stakeholders. *Gerontologist, The*, **2005**, 45, 676-85	5	63
261	Barriers and facilitators of African American participation in Alzheimer disease biomarker research. *Alzheimer Disease and Associated Disorders*, **2010**, 24 Suppl, S24-9	2.5	61
260	Phosphorylated tau-A□2 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. *Biological Psychiatry*, **2014**, 75, 723-31	7.9	58
259	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. *American Journal of Geriatric Psychiatry*, **2016**, 24, 1095-1104	6.5	58
258	The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. *Neurology*, **2013**, 81, 1425-33	6.5	56
257	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. *Brain*, **2015**, 138, 1036-45	11.2	54
256	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. *Brain*, **2018**, 141, 1186-1200	11.2	54
255	Interrater reliability of the Clinical Dementia Rating in a multicenter trial. *Journal of the American Geriatrics Society*, **2000**, 48, 558-9	5.6	54
254	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE □4 genotype. *Brain*, **2018**, 141, 1828-1839	11.2	53
253	Preclinical Alzheimer disease and risk of falls. *Neurology*, **2013**, 81, 437-43	6.5	53
252	Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. *Current Neurology and Neuroscience Reports*, **2014**, 14, 499	6.6	52

251	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. *Neurobiology of Disease*, **2019**, 121, 327-337	7.5	52
250	Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. *Neurology*, **2015**, 84, 1254-60	6.5	51
249	Clinician assessment of the driving competence of patients with dementia. *Journal of the American Geriatrics Society*, **2005**, 53, 829-33	5.6	51
248	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nature Medicine*, **2021**, 27, 1187-1196	50.5	51
247	Clinical Features of Alzheimer Disease With and Without Lewy Bodies. *JAMA Neurology*, **2015**, 72, 789-96	17.2	50
246	The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers. *PLoS Genetics*, **2013**, 9, e1003685	6	49
245	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 655-665	1.2	48
244	BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. *Brain*, **2016**, 139, 2766-2777	11.2	48
243	Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). *Neuropsychology*, **2014**, 28, 19-29	3.8	48
242	Evaluation of cognitive impairment in older adults: combining brief informant and performance measures. *Archives of Neurology*, **2007**, 64, 718-24		48
241	Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). *Neuropathology*, **2015**, 35, 390-400	2	47
240	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 180-190	5.2	46
239	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. *Brain*, **2018**, 141, 1486-1500	11.2	46
238	Role of family history for Alzheimer biomarker abnormalities in the adult children study. *Archives of Neurology*, **2011**, 68, 1313-9		46
237	Factors associated with the onset and persistence of post-lumbar puncture headache. *JAMA Neurology*, **2015**, 72, 325-32	17.2	43
236	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. *Neurology*, **2018**, 91, e313-e318	6.5	43
235	Toward a multifactorial model of Alzheimer disease. *Neurobiology of Aging*, **2012**, 33, 2262-71	5.6	42
234	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 396-406	17.2	41

233	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. *EMBO Molecular Medicine*, **2018**, 10,	12	41
232	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. *Neurology*, **2019**, 92, e1567-e1579	6.5	40
231	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2018**, 67, 95-98	5.6	40
230	Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. *Neurology*, **2014**, 83, 1613-9	6.5	40
229	An interdisciplinary outreach model of African American recruitment for Alzheimer's disease research. *Gerontologist, The*, **2011**, 51 Suppl 1, S134-41	5	38
228	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. *Alzheimer Disease and Associated Disorders*, **2017**, 31, 87-93	2.5	37
227	In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. *NeuroImage*, **2017**, 148, 296-304	7.9	37
226	Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. *Neuropsychology*, **2013**, 27, 516-28	3.8	37
225	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. *NeuroImage: Clinical*, **2018**, 19, 406-416	5.3	37
224	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. *Neurobiology of Aging*, **2017**, 56, 25-32	5.6	36
223	Prevalence of the apolipoprotein E ε4 allele in amyloid β-positive subjects across the spectrum of Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 913-924	1.2	36
222	Upward drift in cerebrospinal fluid amyloid β42 assay values for more than 10 years. *Alzheimer's and Dementia*, **2018**, 14, 62-70	1.2	36
221	Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. *PLoS ONE*, **2014**, 9, e89998	3.7	36
220	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. *Neurobiology of Aging*, **2016**, 43, 23-33	5.6	35
219	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 245-252	5.2	34
218	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. *PLoS ONE*, **2018**, 13, e0195838	3.7	34
217	The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. *Molecular Psychiatry*, **2021**, 26, 614-628	15.1	34
216	Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System. *JAMA Neurology*, **2017**, 74, 207-215	17.2	33

215	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 1197-1206	1.2	32
214	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. *Scientific Reports*, **2017**, 7, 1225	4.9	32
213	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. *Molecular Neurodegeneration*, **2019**, 14, 18	19	32
212	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. *NeuroImage: Clinical*, **2015**, 8, 246-52	5.3	32
211	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurology*, **2021**, 78, 102-113	17.2	32
210	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. *PLoS ONE*, **2016**, 11, e0152082	3.7	31
209	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nature Genetics*, **2021**, 53, 294-303	36.3	31
208	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 1427-1437	1.2	31
207	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. *Neurobiology of Aging*, **2015**, 36, 1771-9	5.6	30
206	Addressing Health Disparities Among Minority Populations: Why Clinical Trial Recruitment Is Not Enough. *JAMA Neurology*, **2020**, 77, 1063-1064	17.2	30
205	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. *Alzheimer's and Dementia*, **2016**, 12, 614-22	1.2	30
204	Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. *JAMA Neurology*, **2015**, 72, 1484-90	17.2	30
203	The Brain Chart of Aging: Machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. *Alzheimer's and Dementia*, **2021**, 17, 89-102	1.2	30
202	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. *Journal of Alzheimer's Disease*, **2018**, 62, 745-756	4.3	29
201	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. *Neurobiology of Aging*, **2016**, 37, 208.e1-208.e9	5.6	29
200	Stability of the Clinical Dementia Rating, 1979-2007. *Archives of Neurology*, **2009**, 66, 773-7		29
199	Ascertainment bias in the clinical diagnosis of Alzheimer disease. *Archives of Neurology*, **2010**, 67, 1364-9		29
198	The neuropathology of Alzheimer disease in African American and white individuals. *Archives of Neurology*, **2006**, 63, 87-90		29

197	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. *Alzheimer's and Dementia*, **2018**, 14, 43-53	1.2	28
196	Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. *Neurobiology of Aging*, **2011**, 32 Suppl 1, S1-3	5.6	28
195	Antecedent biomarkers of Alzheimer's disease: the adult children study. *Journal of Geriatric Psychiatry and Neurology*, **2005**, 18, 242-4	3.8	28
194	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. *Ageing Research Reviews*, **2020**, 57, 100994	12	28
193	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. *Neurology*, **2016**, 86, 1499-506	6.5	27
192	Relationship between late-life hypertension, blood pressure, and Alzheimer's disease. *American Journal of Alzheimer's Disease and Other Dementias*, **2011**, 26, 457-62	2.5	27
191	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. *Genome Medicine*, **2018**, 10, 43	14.4	26
190	Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. *Alzheimer Disease and Associated Disorders*, **2014**, 28, 50-7	2.5	26
189	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. *Neurobiology of Aging*, **2019**, 75, 42-50	5.6	26
188	Widespread distribution of tauopathy in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2018**, 72, 177-185	5.6	26
187	Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. *Alzheimer Disease and Associated Disorders*, **2017**, 31, 69-72	2.5	25
186	Preclinical Alzheimer's disease and longitudinal driving decline. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 74-82	6	25
185	Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. *Alzheimer Disease and Associated Disorders*, **2019**, 33, 87-94	2.5	25
184	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 1149-1159	1.2	24
183	The relevance of cerebrospinal fluid synuclein levels to sporadic and familial Alzheimer's disease. *Acta Neuropathologica Communications*, **2018**, 6, 130	7.3	24
182	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. *Neurology*, **2017**, 88, 1273-1281	6.5	23
181	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. *Neurology*, **2015**, 85, 790-8	6.5	23
180	Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. *Journal of the International Neuropsychological Society*, **2015**, 21, 573-83	3.1	23

179	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. *Neuropsychology*, **2015**, 29, 368-81	3.8	23
178	Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. *F1000Research*, **2016**, 5, 2376	3.6	23
177	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. *Brain*, **2019**, 142, 1429-1440	11.2	22
176	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. *Alzheimer's and Dementia*, **2020**, 16, 821-830	1.2	22
175	Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. *F1000Research*, **2016**, 5, 2376	3.6	21
174	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. *Acta Neuropathologica*, **2020**, 139, 45-61	14.3	21
173	In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. *Neurology*, **2018**, 90, e896-e906	9.5	20
172	Quantitative amyloid imaging using image-derived arterial input function. *PLoS ONE*, **2015**, 10, e0122920	3.7	20
171	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. *Scientific Reports*, **2016**, 6,	4.9	20
170	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. *Alzheimer's and Dementia*, **2020**, 16, 501-511	1.2	20
169	Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. *Biological Psychiatry*, **2010**, 67, 581-3	7.9	19
168	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. *PLoS Genetics*, **2017**, 13, e1007045	6	19
167	Seizures as an early symptom of autosomal dominant Alzheimer's disease. *Neurobiology of Aging*, **2019**, 76, 18-23	5.6	19
166	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 98	9	19
165	Absence of effect of depression on cognitive performance in early-stage Alzheimer disease. *Archives of Neurology*, **2004**, 61, 1265-8		18
164	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101767	5.3	16
163	Proximity to Parental Symptom Onset and Amyloid-Burden in Sporadic Alzheimer Disease. *JAMA Neurology*, **2018**, 75, 608-619	17.2	16
162	Discovery and validation of autosomal dominant Alzheimer's disease mutations. *Alzheimer's Research and Therapy*, **2018**, 10, 67	9	16

161	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1423-1434	5.3	16
160	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. *Molecular Neurodegeneration*, **2020**, 15, 57	19	16
159	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 147-155	5.2	15
158	Heritability and genetic variance of dementia with Lewy bodies. *Neurobiology of Disease*, **2019**, 127, 492-501	7.9	15
157	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. *Neurobiology of Disease*, **2020**, 142, 104960	7.5	15
156	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. *Acta Neuropathologica Communications*, **2020**, 8, 5	7.3	15
155	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. *JAMA Network Open*, **2019**, 2, e1917126	10.4	15
154	A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study. *Journal of Applied Gerontology*, **2019**, 38, 277-289	3.3	15
153	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. *Brain*, **2018**, 141, 3233-3248	11.2	15
152	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. *Cerebral Cortex*, **2020**, 30, 5686-5701	5.1	14
151	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. *Journal of Alzheimer's Disease*, **2020**, 74, 1045-1055	4.3	14
150	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. *Annals of Neurology*, **2018**, 84, 424-435	9.4	14
149	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. *Parkinson's Disease*, **2019**, 2019, 7975407	2.6	14
148	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. *Annals of Neurology*, **2019**, 86, 616-625	9.4	13
147	Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. *Neurology*, **2020**, 95, e3104-e3116	6.5	13
146	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. *Brain*, **2021**, 144, 2176-2185	11.2	13
145	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. *Biological Psychiatry*, **2021**, 89, 776-785	7.9	13
144	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. *Annals of Neurology*, **2021**, 89, 254-265	9.4	13

143	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. *Neurology*, **2021**, 96, e2546-e2557	6.5	12
142	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. *JAMA Neurology*, **2016**, 73, 1125-32	17.2	12
141	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. *Alzheimer's Research and Therapy*, **2018**, 10, 69	9	11
140	Factors Influencing Successful Lumbar Puncture in Alzheimer Research. *Alzheimer Disease and Associated Disorders*, **2017**, 31, 287-294	2.5	11
139	The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia. *Journal of the International Neuropsychological Society*, **2020**, 26, 596-606	3.1	11
138	Effect of escitalopram dose and treatment duration on CSF A□levels in healthy older adults: A controlled clinical trial. *Neurology*, **2020**, 95, e2658-e2665	6.5	11
137	Association between personality and tau-PET binding in cognitively normal older adults. *Brain Imaging and Behavior*, **2020**, 14, 2122-2131	4.1	11
136	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 669-677	5.2	11
135	Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 74, 1085-1095	4.3	10
134	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. *Neurobiology of Aging*, **2016**, 38, 104-111	5.6	10
133	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. *Frontiers in Neuroscience*, **2018**, 12, 209	5.1	10
132	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. *Alzheimer's and Dementia*, **2019**, 15, 506-514	1.2	10
131	A comprehensive screening of copy number variability in dementia with Lewy bodies. *Neurobiology of Aging*, **2019**, 75, 223.e1-223.e10	5.6	10
130	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. *Annals of Neurology*, **2018**, 84, 741-753	9.4	10
129	Higher Body Mass Index Is Associated with Lower Cortical Amyloid-□Burden in Cognitively Normal Individuals in Late-Life. *Journal of Alzheimer's Disease*, **2019**, 69, 817-827	4.3	9
128	Spatial navigation ability predicts progression of dementia symptomatology. *Alzheimer's and Dementia*, **2020**, 16, 491-500	1.2	9
127	Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities. *Alzheimer Disease and Associated Disorders*, **2018**, 32, 101-106	2.5	9
126	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. *JAMA Neurology*, **2022**,	17.2	9

125	Genomic and multi-tissue proteomic integration for understanding the biology of disease and other complex traits		9
124	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF- in APOE4 carriers. *Neurobiology of Aging*, **2020**, 86, 112-122	5.6	9
123	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. *Nature Communications*, **2021**, 12, 3825	17.4	9
122	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. *Nature Neuroscience*, **2021**, 24, 1302-1312	25.5	9
121	Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. *Journal of Alzheimer's Disease*, **2017**, 58, 675-680	4.3	8
120	Tailored Calendar Journals to Ascertain Falls Among Older Adults. *OTJR Occupation, Participation and Health*, **2015**, 35, 53-9	1.3	8
119	GPS driving: a digital biomarker for preclinical Alzheimer disease. *Alzheimer's Research and Therapy*, **2021**, 13, 115	9	8
118	Comparing amyloid- plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. *Acta Neuropathologica*, **2021**, 142, 689-706	14.3	8
117	Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. *Alzheimer Disease and Associated Disorders*, **2019**, 33, 15-20	2.5	8
116	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. *Journal of Neurochemistry*, **2020**, 152, 235-251	6	8
115	Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 141-142	17.2	8
114	Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. *Archives of Clinical Neuropsychology*, **2019**, 34, 1138-1155	2.7	7
113	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. *NeuroImage: Clinical*, **2020**, 26, 102248	5.3	7
112	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. *JAMA Network Open*, **2019**, 2, e1913491	10.4	7
111	Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018. *Alzheimer's and Dementia*, **2020**, 16, 1734-1744	1.2	7
110	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. *Neurology: Genetics*, **2021**, 7, e571	3.8	7
109	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. *Neurology*, **2021**, 97, e76-e87	6.5	7
108	The informed road map to prevention of Alzheimer Disease: A call to arms. *Molecular Neurodegeneration*, **2021**, 16, 49	19	7

107	Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. *Alzheimer's and Dementia*, **2018**, 14, 610-616	1.2	6
106	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. *Translational Psychiatry*, **2021**, 11, 585	8.6	6
105	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. *Brain Communications*, **2020**, 2, fcaa102	4.5	6
104	Falls Associate with Neurodegenerative Changes in ATN Framework of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 77, 745-752	4.3	6
103	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. *Neurobiology of Aging*, **2020**, 96, 233-245	5.6	6
102	Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. *Brain*, **2021**,	11.2	6
101	Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. *Alzheimer Disease and Associated Disorders*, **2018**, 32, 291-297	2.5	6
100	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 669-676	6	6
99	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. *Nature Communications*, **2021**, 12, 5346	17.4	6
98	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. *Alzheimer's and Dementia*, **2020**, 16, 589-597	1.2	6
97	Multi-Modal Home Sleep Monitoring in Older Adults. *Journal of Visualized Experiments*, **2019**,	1.6	5
96	Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12103	6	5
95	Deciphering the factors that influence participation in studies requiring serial lumbar punctures. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12003	5.2	5
94	Variant-dependent heterogeneity in amyloid □burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.. *Lancet Neurology, The*, **2022**, 21, 140-152	24.1	5
93	Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning. *Alzheimer Disease and Associated Disorders*, **2020**, 34, 212-219	2.5	5
92	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. *Brain Connectivity*, **2021**, 11, 239-249	2.7	5
91	Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals. *Journal of Infectious Diseases*, **2019**, 220, 68-72	7	5
90	Lack of association between acute stroke, post-stroke dementia, race, and □amyloid status. *NeuroImage: Clinical*, **2021**, 29, 102553	5.3	5

89	Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. *Journal of Alzheimer's Disease*, **2018**, 66, 1213-1221	4.3	5
88	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. *Neurology*, **2021**, 97, e1823-e1834	6.3	5
87	Modeling autosomal dominant Alzheimer's disease with machine learning. *Alzheimer's and Dementia*, **2021**, 17, 1005-1016	1.2	5
86	Dopamine D1+D3 receptor density may correlate with parkinson disease clinical features. *Annals of Clinical and Translational Neurology*, **2021**, 8, 224-237	5.3	5
85	Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2020**, 7, 2475-2480	5.3	4
84	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 74, 1119-1129	4.3	4
83	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). *Alzheimer's and Dementia*, **2020**, 16, 219-228	1.2	4
82	Using the A/T/N Framework to Examine Driving in Preclinical AD. *Geriatrics (Switzerland)*, **2018**, 3,	2.2	4
81	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2018**, 61, 509-513	4.3	4
80	Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults. *SLEEP Advances*, **2020**, 1, zpaa006	2.8	4
79	Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument. *Alzheimer Disease and Associated Disorders*, **2020**, 34, 112-117	2.5	4
78	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. *NeuroImage: Clinical*, **2020**, 28, 102491	5.3	4
77	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. *Acta Neuropathologica Communications*, **2020**, 8, 196	7.3	4
76	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
75	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. *Journal of Alzheimer's Disease*, **2020**, 77, 1469-1482	4.3	4
74	Adaptation of the Clinical Dementia Rating Scale for adults with Down syndrome. *Journal of Neurodevelopmental Disorders*, **2019**, 11, 39	4.6	4
73	Driving in the elderly in health and disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2019**, 167, 563-573	3	4
72	Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes. *Alzheimer's and Dementia*, **2021**, 17, 653-664	1.2	4

71	Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept. *Journal of Alzheimer's Disease*, **2021**, 79, 1009-1014	4.3	4
70	Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals. *Journal of Alzheimer's Disease*, **2021**, 79, 1801-1811	4.3	4
69	O1-04-03: COMPARING SMARTPHONE-ADMINISTERED COGNITIVE ASSESSMENTS WITH CONVENTIONAL TESTS AND BIOMARKERS IN SPORADIC AND DOMINANTLY INHERITED ALZHEIMER DISEASE **2018**, 14, P224-P225		4
68	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. *Alzheimer's and Dementia*, **2021**,	1.2	4
67	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. *Neurology*, **2021**, 96, e1632-e1645	6.5	4
66	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. *Lancet Neurology, The* , **2022**, 21, 329-341	24.1	4
65	Effect of Race on Prediction of Brain Amyloidosis by Plasma A□2/A□0, Phosphorylated Tau, and Neurofilament Ligh.. *Neurology*, **2022**,	6.5	4
64	Latent structure of cognitive performance in the adult children study. *Journal of Clinical and Experimental Neuropsychology*, **2017**, 39, 621-635	2.1	3
63	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. *Alzheimer's and Dementia*, **2019**, 15, 1448-1457	1.2	3
62	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing.. *Journal of Clinical and Experimental Neuropsychology*, **2022**, 1-13	2.1	3
61	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer□ disease, irrespective of fibrillar amyloid-beta pathology		3
60	Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results. *Journal of Alzheimer's Disease*, **2021**, 79, 559-572	4.3	3
59	P4-108: RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE **2018**, 14, P1480-P1480		3
58	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. *Translational Psychiatry*, **2021**, 11, 483	8.6	3
57	Prion-like □synuclein pathology in the brain of infants with Krabbe disease.. *Brain*, **2022**,	11.2	2
56	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. *Nature Communications*, **2021**, 12, 7065	17.4	2
55	Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults. *Journal of Racial and Ethnic Health Disparities*, **2020**, 7, 269-280	3.5	2
54	Association of education with A□burden in preclinical familial and sporadic Alzheimer disease. *Neurology*, **2020**, 95, e1554-e1564	6.5	2

53	Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation. *Journal of Alzheimer's Disease*, **2021**, 80, 133-142	4.3	2
52	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. *Psychological Science*, **2021**, 32, 849-860	7.9	2
51	Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau. *Alzheimer's and Dementia*, **2021**,	1.2	2
50	Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. *Brain, Behavior, and Immunity*, **2021**, 94, 299-307	16.6	2
49	IC-01-03: Classifying TAU Pet Positivity With [18F]-AV-1451 in Preclinical Alzheimer's Disease **2016**, 12, P2-P3		2
48	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. *Journal of Cognitive Neuroscience*, **2021**, 33, 279-302	3.1	2
47	Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. *Neurobiology of Aging*, **2021**, 98, 116-123	5.6	2
46	Item response theory analysis of the Clinical Dementia Rating. *Alzheimer's and Dementia*, **2021**, 17, 534-542	14.2	2
45	The ideological divide in confidence in science and participation in medical research. *Scientific Reports*, **2021**, 11, 3120	4.9	2
44	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.. *Alzheimer's and Dementia*, **2022**,	1.2	2
43	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	2
42	Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 450-457	6	1
41	Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies. *Alzheimer Disease and Associated Disorders*, **2018**, 32, 179-184	2.5	1
40	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease **2015**, 11, P533-P534		1
39	Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.. *Neurobiology of Aging*, **2022**, 112, 181-190	5.6	1
38	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.. *Neurobiology of Disease*, **2022**, 105662	7.5	1
37	Intracranial internal carotid artery calcification is not predictive of future cognitive decline.. *Alzheimer's Research and Therapy*, **2022**, 14, 32	9	1
36	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2021**, 7, e12226	6	1

35	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain		1
34	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. *Neurobiology of Aging*, **2020**, 96, 165-175	5.6	1
33	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12038	5.2	1
32	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
31	Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures. *Journal of Nuclear Medicine*, **2021**,	8.9	1
30	Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. *Neurobiology of Aging*, **2021**, 102, 64-72	5.6	1
29	O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer's Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) **2016**, 12, P226-P226		1
28	IC-P-021: LONGITUDINAL CHANGES IN FUNCTIONAL CONNECTIVITY IN CONVERSION TO SYMPTOMATIC AD **2019**, 15, P29-P29		1
27	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. *Journal of Alzheimer's Disease*, **2021**, 79, 895-903	4.3	1
26	Lack of evidence supporting a role for DPP6 sequence variants in Alzheimer's disease in the European American population. *Acta Neuropathologica*, **2021**, 141, 623-624	14.3	1
25	Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3172-3186	8.8	1
24	Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class case-Application to the early diagnosis of Alzheimer disease. *Statistical Methods in Medical Research* , **2018**, 27, 701-714	2.3	1
23	P3-251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD **2018**, 14, P1170-P1170		1
22	P1-288: THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)-ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) COMPARISON STUDY: CHALLENGES AND OPPORTUNITIES **2018**, 14, P395-P396		1
21	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. *BMJ Open*, **2021**, 11, e050820	3	1
20	Regional age-related atrophy after screening for preclinical alzheimer disease. *Neurobiology of Aging*, **2021**, 109, 43-51	5.6	1
19	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI		1
18	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression.. *JAMA Psychiatry*, **2022**,	14.5	1

17	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease.. *NeuroImage*, **2022**, 119228	7.9	1
16	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90.. *Scientific Reports*, **2022**, 12, 6117	4.9	1
15	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. *PLoS ONE*, **2022**, 17, e0267298	3.7	1
14	Assessing the Reliability of Reported Medical History in Older Adults. *Journal of Alzheimer's Disease* , **2020**, 78, 643-652	4.3	0
13	Validation of AD8-Philippines (AD8-P): A Brief Informant-Based Questionnaire for Dementia Screening in the Philippines. *International Journal of Alzheimer's Disease*, **2021**, 2021, 7750235	3.7	0
12	Dissection of the polygenic architecture of neuronal A□production using a large sample of individual iPSC lines derived from Alzheimer□ disease patients. *Nature Aging*, **2022**, 2, 125-139		0
11	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease.. *Acta Neuropathologica Communications*, **2022**, 10, 29	7.3	0
10	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.. *Nature Communications*, **2022**, 13, 1495	17.4	0
9	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer's disease.. *Neurobiology of Disease*, **2022**, 105714	7.5	0
8	Naturalistic driving measures of route selection associate with resting state networks in older adults.. *Scientific Reports*, **2022**, 12, 6486	4.9	0
7	Reply to "Excess amyloid beta can be degraded in healthy humans". *Annals of Neurology*, **2018**, 83, 650-65□	9.4	
6	[P3□63]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER's DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE **2017**, 13, P1043-P1044		
5	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limits-Application to diagnosing early stage Alzheimer disease.. *Statistical Methods in Medical Research*, **2022**, 9622802211072511	2.3	
4	Replication study of AD-associated rare variants.. *Alzheimer's and Dementia*, **2022**,	1.2	
3	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network **2016**, 12, P378-P379		
2	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12197	5.2	
1	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. *Alzheimer's Research and Therapy*, **2021**, 13, 153	9	